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A live RSV vaccine with engineered thermostability
is immunogenic in cotton rats despite high
attenuation
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Jorge C.G. Blanco8, Pedro A. Piedra9,10, Elizabeth R. Wright1,2,4 & Martin L. Moore1,2
Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization and there
remains no pediatric vaccine. RSV live-attenuated vaccines (LAVs) have a history of safe
testing in infants; however, achieving an effective balance of attenuation and immunogenicity
has proven challenging. Here we seek to engineer an RSV LAV with enhanced immuno-
genicity. Genetic mapping identifies strain line 19 fusion (F) protein residues that correlate
with pre-fusion antigen maintenance by ELISA and thermal stability of infectivity in live RSV.
We generate a LAV candidate named OE4 which expresses line 19F and is attenuated by
codon-deoptimization of non-structural (NS1 and NS2) genes, deletion of the small hydro-
phobic (SH) gene, codon-deoptimization of the attachment (G) gene and ablation of the
secreted form of G. OE4 (RSV-A2-dNS1-dNS2-DSH-dGm-Gsnull-line19F) exhibits elevated
pre-fusion antigen levels, thermal stability, immunogenicity, and efficacy despite heavy
attenuation in the upper and lower airways of cotton rats.
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I
n the 1960s, a formalin-inactivated RSV (FI-RSV) vaccine
primed for enhanced illness in infants on natural infection1.
This phenomenon was replicable in animal models
and considered dependent on RSV naive status2. Subsequent
studies using subunit-based vaccines also primed for
immunopathology in animals3,4. These early RSV vaccines
encouraged development of LAVs, which do not prime for
enhanced disease in animals or seronegative infants2,5. However,
development of pediatric RSV LAV strains with sufficient
attenuation and immunogenicity has been difficult6. To address
these dual challenges, newer RSV LAVs have incorporated genetic
modifications rationally designed to retain or enhance
immunogenicity compared with wild-type virus7–9 because
natural infection may be suboptimally immunogenic for LAVs
derived by classic attenuation methods.
Recent elucidation of the structure of the pre-fusion
conformation of RSV F protein (pre-F10) and discovery of
its importance as a natural immunogen11 has had implications
for RSV vaccine development. The high capacity of pre-F to
elicit neutralizing antibody titres has been demonstrated in
multiple vaccine platforms, including purified proteins12–14,
virus-like particles15, and recombinant parainfluenza viruses16.
Use of pre-F in passive immunization, either by anti-pre-F
monoclonal antibody (mAb) prophylaxis or by boosting
RSV neutralizing antibody (nAb) titres in pregnant mothers
with pre-F protein-based vaccines, holds promise for reducing
RSV disease in the youngest infants14. Nevertheless, active
immunization of infants with a replicating RSV vaccine
could potentially have a large child health benefit if protection
spanned beyond the persistence of passively acquired maternal
Ab. Since natural RSV infection induces anti-pre-F nAb11,
we hypothesized that RSV with enhanced pre-F expression
would have increased LAV immunogenicity.
Here we first identified a chimeric RSV strain A2-line19F
with enhanced pre-fusion antigen levels, thermostability and
immunogenicity compared with parental strain A2. We then
incorporated line19F into an RSV LAV candidate ‘OE4’ with the
genotype RSV-A2-dNS1- dNS2-DSH-dGm-Gsnull-line19F.
We found that OE4 exhibited elevated pre-fusion antigen levels,
thermal stability, immunogenicity, and efficacy despite
heavy attenuation in the upper and lower airways of cotton rats.
Results
Pre-fusion F ELISAs. Metastable pre-F undergoes a dynamic
transition to form a thermodynamically stable six-helix post-
fusion bundle that facilitates viral and host membrane fusion10,14.
Since both pre-F and post-F are present on RSV virions
in prepared virus stocks17,18, we evaluated the relative amount
of pre-F antigen in RSV stocks using an ELISA-based approach
to compare MPE8 with motavizumab antibody binding. MPE8
is a human monoclonal antibody that preferentially binds to
two highly conserved anti-parallel b-strands on pre-F, which
are rearranged in the post-fusion conformation to render
them less accessible to antibody binding19. Motavizumab,
in contrast, stably binds to both pre- and post-fusion F. We
found that strain A2-line19F, which expresses the F protein
of strain line 19 in the background of the prototypical
A2 strain20,21, exhibited significantly higher relative binding to
MPE8 than did strain A2 (Fig. 1a). We confirmed this finding
using the human monoclonal antibody D25, which binds to a
distinct antigenic site on pre-F (antigenic site Ø)10 with
even greater specificity than MPE8 (ref. 22). We found that
A2-line19F exhibited higher relative binding to D25 than A2,
which was similar in magnitude and correlated with MPE8
binding (Fig. 1b).
Five unique amino-acid residues distinguish line 19F from
A2 F: M79, R191, K357, Y371 and I557 (Supplementary Fig. 1)20.
We generated A2-line19F mutants by substituting A2 residues in
place of the unique line 19F residues20. To determine the
effects of these residues on pre-F antigen levels in virus stocks, we
performed MPE8 and motavizumab ELISAs on the recombinant
A2-line19F mutant viruses. We found that residues M79,
K357 and Y371 contributed to line 19 F pre-F antigen levels
(Fig. 1a). These results were consistent with previous data
showing that the K357/Y371 residues together impeded
A2-line19F fusion activity in vitro20.
Thermal stability assays. We next evaluated the thermal stability
of A2-line19F compared with A2. RSV is known to be a
heat-labile virus, and elevated temperatures can trigger the
transition from pre- to post-fusion F23. We therefore
hypothesized that RSV with enhanced pre-F levels would be
more resistant to temperature inactivation. We analysed
thermostability at 4 and 37 C because thermostability at
4 C may have implications for retention of vaccine potency in
cold chain, whereas thermostability at 37 C has more relevance
for physiological conditions. We found that RSV A2-line19F
infectivity was more thermostable over time than A2 at
both temperatures (Fig. 2a,b), a phenotype that was mediated
in part by the residues K357 and Y371 (Fig. 2c). We then
introduced K357 and Y371 into the F of a genetically divergent
vaccine strain DB1, which expresses a consensus F gene of the
antigenic subgroup B ‘Buenos Aires’ (BAF) clade. We previously
described the generation of DB1, which also contains
codon-deoptimized non-structural protein genes and deleted
SH gene, with a genotype RSV-A2-dNS1-dNS2-DSH-BAF9. DB1
expressed low levels of pre-F antigen and was thermally unstable;
however, incorporation of the K357 and Y371 residues to
generate DB1–357/371 enhanced MPE8 binding (Fig. 1a)
and partially restored thermal stability (Fig. 2d). These data
demonstrated that residues 357 and 371 modulated not only
MPE8 binding, a correlate of pre-F antigen levels, but also viral
resistance to thermal inactivation in viral stocks.
Generation of RSV live-attenuated vaccine OE4. We next
generated a novel RSV LAV called OE4, by incorporating line
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Figure 1 | MPE8 and D25 ELISAs. (a) Ratio of direct ELISA using MPE8, a
pre-F-specific mAb, to direct ELISA using motavizumab, a total F mAb.
Values are normalized to strain A2. For A2-line19F mutants, the asterisks
show significant differences compared with A2-line19F. (b) Ratio of direct
ELISA using D25, another pre-F-specific mAb, to direct ELISA using
motavizumab. All graphs represent the meansþ s.d.’s of at least two
experimental replicates, and data were analysed by one-way ANOVA.
When significant, P values are shown as a bracket between groups
(Po0.0005) or by asterisk when compared with A2-line19F
(*Po0.05; **Po0.005; ***Po0.0005).
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19F into a multi-component vaccine designed to achieve
attenuation, improved immunogenicity and genetic stability.
We previously codon-deoptimized the NS1 and NS2 genes, which
encode two nonstructural proteins of RSV that suppress
host innate immunity by targeting interferon pathways and
suppressing apoptosis24,25. Codon deoptimization of NS1 and
NS2 genes was genetically stable and reduced NS1 and
NS2 protein expression, resulting in virus attenuation with
slightly enhanced immunogenicity in mice8. We subsequently
deleted the small hydrophobic (SH) protein gene with the goal of
increasing the transcription of downstream viral genes, including
F, by altering their proximity to the viral leader26. The deletion of
SH is also mildly attenuating in mice and chimpanzees,
but conferred no apparent attenuation in a vaccine candidate in
children26–28. Last, we codon-deoptimized the RSV attachment
(G) glycoprotein gene and ablated the secreted form of G by
a point mutation. RSV expresses a membrane-bound form
(Gm) and a secreted form (Gs) of G, which are not required for
viral replication in immortalized cell lines29–32. RSV G is capable
of eliciting protective neutralizing antibodies33. However, G is
less conserved than F and suppresses the innate immune response
through chemokine mimicry34,35. Gs functions as an antigen
decoy and can alter dendritic cell signalling and activation
through interactions with C-type lectins36,37. The resulting
genotype of the OE4 vaccine candidate was RSV-A2-dNS1-
dNS2-DSH-dGm-Gsnull-line19F (Fig. 3a). Using western blotting,
we demonstrated that OE4 had decreased expression levels
of NS1, NS2 and G as expected compared with parental
A2 (Fig. 3b,c). We additionally found that OE4 had higher
levels of F expression than A2-line19F, likely attributable to the
deletion of SH (Fig. 3d,e).
Analysis of OE4 surface glycoproteins. We analysed the MPE8
and D25 binding of OE4 and measured vaccine thermal stability
at 4 and 37 C. Similar to A2-line19F, OE4 exhibited high relative
pre-F antigen levels by antibody binding (Fig. 1a,b) and thermal
stability (Fig. 2a,b) consistent with its expression of the line
19F protein. We further explored this relationship by quantifying
pre-F stability as measured by MPE8 binding of OE4 and
A2 from virus stocks incubated at 4 C over time. Relative pre-F
antigen levels declined in both viruses over a period of 8 days
(Supplementary Fig. 2a). Therefore, the kinetics of thermal
stability of A2 and OE4 infectivity did not correlate with the
decay of pre-F antigen levels. However, OE4 maintained greater
than twice the levels of pre-F antigen levels at each time point
compared with A2 (Supplementary Fig. 2b), and a minimal
threshold of pre-F may be sufficient to maintain infectivity.
In order to assess the overall structure of the virions
and glycoprotein incorporation into RSV A2 and OE4, we then
performed thin-section transmission electron microscopy (TEM),
native immuno-TEM, and cryo-electron tomography (cryo-ET)
of viruses budded from BEAS-2B cells, an immortalized human
bronchial epithelial cell line. In all cases, virus-infected cells
and released virions were analysed following minimal sample
processing to maximize preservation of the native structure of
the virions. First, native immunogold labelling combined with
thin-section TEM was performed using mAbs that preferentially
bound pre-F (MPE8), post-F (131-2A), total F (motavizumab) or
G (131-2G) (Fig. 4a)38. The density of gold particles per
membrane length was quantified for each virus and
immunolabel (Fig. 4b)39. OE4 virus particles exhibited a greater
density of incorporated pre-F and total F than A2, potentially due
to the deletion of SH. There was no significant difference in the
amount of post-F detected on the surfaces of A2 and
OE4 particles. G protein density on OE4 particles
was significantly reduced, as was expected in the setting of
codon-deoptimization of the G gene.
When visualized by cryo-ET, A2 and OE4 virus particles
were morphologically similar and formed filaments with
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Figure 2 | Thermal stability assays. Thermal inactivation was carried out either by incubation of virus at 4 C (a,c,d) or 37 C (b). The viruses in c labelled
79, 191, 357, 371, 557 and 357/371 represent A2-line19F containing substitutions at these indicated positions with A2 residues. The virus in c labelled
DB1-357/371 represents DB1 with substitutions of line 19F residues at positions 357 and 371. Viruses were harvested at the indicated time points and
titrated by FFU or PFU assays. All graphs represent the meansþ s.d.’s of at least two experimental replicates combined, and data were analysed by
two-way ANOVA (*Po0.05; **Po0.005; ***Po0.0005; ****Po0.00005).
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abundant glycoprotein spikes on the surface, matrix protein
lining the inside of the viral membrane, and ribonucleoprotein
complex in the interior of the virions (Fig. 5a–c)17,18,38.
To further investigate the conformations of RSV F on the
surfaces of A2 and OE4 virions in their native states, we then
calculated subvolume averages of F structures from the cryo-ET
data. These studies demonstrated that the majority of F proteins
on both viruses in their native states immediately after budding
was in the pre-F conformation (Fig. 5). The application of
heat (55 C for 30min) triggered the conformational change from
pre- to post-F, providing direct evidence of the relationship
between temperature and pre-F stability (Fig. 5c,f,i,j).
Characterization of OE4 in cell culture and primary cells.
We next characterized the OE4 vaccine candidate in vitro by
measuring attenuation levels in immortalized cells and in primary
human airway epithelial cells (Fig. 6). In Vero cells, which
were used for virus stock generation, OE4 grew to titres slightly
below the parental unattenuated A2-line19F (Fig. 6a). OE4 was
more attenuated relative to wild type in BEAS-2B cells (Fig. 6b).
We then evaluated OE4 growth in primary human airway
epithelial cells, which are an established system for approximating
RSV LAV attenuation in seronegative children40. We
implemented two models, NHBE-ALI and HAE-ALI, and
found that OE4 was significantly attenuated in both models
(Fig. 6c,d) and exhibited deficiency in spreading through
the cultures (Fig. 6e). The codon deoptimization of G in
OE4 contributed significantly to the level of attenuation
compared with OE4 expressing wild-type G (OE4þwtG) in
NHBE-ALI (Fig. 6c), likely due to the previously described
attachment role of G in primary cells30.
Characterization of OE4 in BALB/c mice. To measure relative
levels of attenuation in vivo, we inoculated mice intranasally (i.n.)
and measured lung viral loads on days 2, 4, 6 and 8 post infection.
We found that OE4 was moderately attenuated compared
with A2 and A2-line19F in this model (Fig. 7a). We compared
lung viral loads of mice inoculated with OE4 with and without
the mKate2 gene and found that reporter had no effect on
viral attenuation (Supplementary Fig. 3), consistent with pre-
viously published results41. We sequenced the NS1, NS2, G and
F genes of OE4 from virus recovered from mouse lungs on day
6 post infection, and there were no mutations in these genes.
To analyse immunogenicity, we then vaccinated mice and
measured nAb titres on days 35, 70 and 100 and found that
OE4 elicited nAb titres equivalent to A2-line19F and higher than
A2 at each time point post infection (Fig. 7b). Following
i.n. inoculation, the mice were then challenged on day 102 with
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Figure 3 | Design of live-attenuated vaccine OE4 and expression of viral proteins. (a) Schematic of RSV LAV OE4 genome including codon
deoptimization of the NS1, NS2 and G genes, deletion of the SH gene, and incorporation of the line 19F gene. (b) Western blotting of Vero cells infected with
A2 (white), OE4 (green) or OE4 expressing wild-type G (OE4-wtG, grey) for NS1, NS2, N and G. An A2-Gnull mutant was included as a control.
(c) Western densitometry analyses were normalized to A2 expression levels. (d) Western blotting of Vero cells infected with mock, A2-line19F (white),
OE4-wtG (grey) or OE4 (green) for F, N and GAPDH. (e) Densitometry results were normalized to A2 expression levels. Densitometry results represent
the meansþ s.d.’s of at least two experimental replicates and representative blots are shown. Statistical analyses were performed by one-way ANOVA
(***Po0.0005; ****Po0.00005). d, codon-deoptimized; F, fusion protein; G, attachment glycoprotein; L, large polymerase; M, matrix; mK2, monomeric
Katushka2; N, nucleoprotein; NS1/NS2, nonstructural proteins 1 and 2; P, phosphoprotein; SH, small hydrophobic protein.
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A2-line19F, and the OE4-vaccinated mice were completely
protected against the challenge (Fig. 7c). We next measured
OE4 mucus production in the lungs of mice. We previously
demonstrated that A2-line19F induces increased airway mucin
expression, a measure of pathogenicity in this model20,21.
However, OE4, which also expresses line 19F, induced
lower levels of airway mucin expression than A2-line19F in
mice (Fig. 7d and Supplementary Fig. 4), indicating that
the attenuating genetic modifications in OE4 modulated the
mucogenic phenotype. Subsequently, we compared OE4-induced
mucin expression with a reconstituted RSV mutant containing a
deletion of M2-2 (A2-del-M2-2), the primary genetic modifi-
cation of a clinically advanced LAV candidate7. The deletion of
M2-2 results in reduced viral replication and elevated
transcription of downstream RSV genes (for example, NS1,
NS2, SH, G, F and so on), which represents a different attenua-
tion strategy than OE4. It should be noted that our reconstituted
A2-del-M2-2 is not identical to MEDI-DM2-2 due to minor
genetic differences between the A2 backbones. Because the
deletion of M2-2 results in increased levels of non-essential
virulence proteins, we hypothesized that A2-del-M2-2 would
be mucogenic in mice. Compared with OE4, we found that
A2-del-M2-2 induced significantly more airway mucin expression
(Fig. 7d and Supplementary Fig. 4).
Characterization of OE4 in cotton rats. OE4 attenuation
and immunogenicity were next evaluated in cotton rats, a more
permissive model of RSV infection. In cotton rats, OE4 was
highly attenuated in the upper and lower respiratory tracts, and
more attenuated than A2-del-M2-2 (Fig. 7e,f). Despite significant
attenuation, OE4 induced relatively high levels of serum
nAb against a panel of RSV strains representing RSV diversity
(Fig. 7g). OE4-vaccinated cotton rats were completely protected
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Figure 4 | Immunogold labelling of RSV surface glycoproteins F and G.
(a) Representative TEM images of BEAS-2B cells infected at an MOI of
10 with A2 (black) or OE4 (green) and labelled with MPE8 (pre-F mAb),
131-2A (post-F mAb), Motavizumab (total F mAb) or 131-2G (G mAb) and
probed with gold-labelled secondary antibodies. (b) Quantification of the
amount of immunogold particles per measured membrane length per virion.
For each labeling condition, more than 100 virions (graph data points) were
evaluated for each virus. The red lines represent the mean particle densities
along the membrane for each condition. Significant differences are
indicated by ***Po0.0005 determined by t-test with Welch’s correction.
Scale bars represent 200nm.
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Figure 5 | Cryo-electron tomography of RSV virions and subvolume
averaging of the F glycoprotein. (a–c) Tomographic slices (6.14 nm) of A2,
OE4 and A2-heat (55 C for 30min) virions showing overall virus structure
and the organization of surface glycoproteins (insets). Inset in OE4 is
rotated 180. Scale bars are 200 nm for A2 and OE4, and 100nm for
A2-heat. (d–l) Subvolume averages and modelling of RSV F structures in
pre- and post-fusion conformations. Central slices (6.14Å in thickness) of
the averaged structures lowpass filtered to 40Å for A2 (d), OE4 (e) and
A2-heat (f). Quasi-atomic models generated by fitting the RSV pre-fusion
F (PDB ID 4JHW) and RSV post-fusion F (PDB ID 3RRT) crystal structures
into the subvolume averages, with side views (g–i) and top views (j–l) for
A2 (g,j), OE4 (h,k) and A2-heat (i,l). Note the height difference between
the ectodomain of A2/OE4 and A2-heat. The measurements were made
from the top of the membrane to the top of the head domain. Scale bars,
10 nm (d–f); 5 nm (g–l).
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against RSV challenge, not only in lungs (Fig. 7h) but also in
the upper respiratory tracts (Fig. 7i). Thus, OE4 established
effective mucosal immunity despite being highly attenuated in
cotton rats.
Last, a primary concern highlighted by the failure of the
FI-RSV vaccine candidate is the potential for vaccine-enhanced
priming for disease on natural RSV infection. Although RSV
LAV candidates have not been shown to cause enhanced illness,
we evaluated whether the novel vaccination strategy employed
by OE4 would prime for enhanced disease upon challenge in
cotton rats. Results demonstrated that RSV challenge did not
cause enhanced histopathology following infection with
OE4 compared with mock (Fig. 8). In contrast, FI-RSV
did result in enhanced disease associated with elevated
peribronchiolar infiltration and alveolitis.
Discussion
We identified a chimeric RSV strain A2-line19F that
had increased relative MPE8 binding, increased thermal stability
in viral stocks and increased immunogenicity in vivo compared
with parental strain A2. A2-line19F differs from A2 by only
five unique residues within the F protein. Incorporation of two
of these residues (357/371) into a heterologous vaccine strain
DB1 conferred increased relative MPE8 binding and increased
thermal stability at 4 C. To exploit these properties in an
RSV LAV, we incorporated the line 19F protein into a rationally
designed vaccine candidate OE4 with the genotype RSV-A2-
dNS1-dNS2-DSH-dGm-GSnull-line19F. Like A2-line19F, OE4 had
increased relative MPE8 and D25 binding and increased thermal
stability compared with RSV A2. OE4 was also immunogenic
and highly efficacious in BALB/c mice and cotton rats, despite
significant levels of attenuation in vitro and in vivo.
The mutations incorporated into OE4 were genetically stable
in virus recovered from BALB/c mice. Furthermore, lung
histopathologic staining demonstrated that OE4 was not
mucogenic in mice, nor did it cause enhanced histopathology
following RSV challenge in cotton rats.
One inherent limitation of our study is that neither mice
nor cotton rats fully recapitulate RSV disease in humans. In our
study, for example, we observed a difference in the attenuation
levels of OE4 in our two animal models. Whereas OE4 was highly
attenuated in cotton rats and in human primary airway epithelial
cells, it was less attenuated in BALB/c mice. We also found
that OE4 was more immunogenic in BALB/c mice than in cotton
rats. We suspect these discrepancies were attributable to strain-
specific differences in the attachment and infectivity of the line
19F protein and the differential effects of codon-deoptimized
G protein in cotton rats compared with mice. For example,
Teng et al. demonstrated that deletion of G from an RSV clinical
stain was completely attenuating in cotton rats32, whereas
Widjojoatmodjo et al.42 found that RSV-DG was only
moderately attenuated in mice. Nevertheless, OE4 was
significantly attenuated in both animal models and was capable
of inducing protective neutralizing antibodies.
A second limitation of our study relates to the utilization
of MPE8 and D25 ELISAs to quantify pre-F antigen levels in
viral stocks. Both MPE8 and D25 are monoclonal antibodies
that preferentially bind to the pre-fusion conformation of
F; however, the conformational specificities of these two
antibodies have not been fully validated. MPE8, in particular,
competes with palivizumab19 and binds only 10–20 times better
to pre- than post-fusion F22. D25, in contrast, binds at the apex
of the pre-fusion trimer at the antigenic site Ø which undergoes
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marked structural rearrangement upon transition to post-F
(ref. 10). Thus, D25 binds with even greater specificity to pre-
than post-F (100-fold); ref. 22. Nevertheless, limited cross-
reactivity with post-F has been observed, and a monomeric
form of F has also been identified which retains pre-fusion-
specific epitopes13,43. Despite these limitations, both MPE8 and
D25 demonstrate relatively high pre-F specificity, and generated
consistent results among the viruses analysed in this study.
Native immunogold labelling combined with thin-section
TEM also demonstrated increased pre-F and total F on
the surface of OE4 compared with A2. We suspect the increased
incorporation of total F into OE4 was attributable to the
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deletion of the SH gene, which shifted the F gene towards
the viral promoter. The vast majority of F in both OE4 and
A2 was in the pre-fusion conformation, likely because the virions
were maintained in their native states and not subjected to
viral harvesting and stock preparation. Subvolume averaging of
the F structures confirmed that the majority of F was in the
pre-fusion conformation. However, application of heat to
A2 triggered the conformational change to post-F, clearly
demonstrating a relationship between temperature and pre-F
stability. Although these results demonstrate that heat triggers the
transition from pre- to post-fusion F, the relationship between
temperature and pre-F stability remains incompletely defined.
Similarly, the favourable immunogenicity to attenuation profile of
OE4 is likely multifactorial and cannot be attributed specifically
to the expression of pre-fusion F or to thermostability.
In conclusion, we identified key molecular determinant
positions of RSV line 19F which were associated with both
thermal stability and the availability of the pre-F antigen.
Genetically modifying these residues to thermally stabilize and
boost immunogenicity of RSV LAVs represents a promising new
approach to next-generation RSV vaccine design. Using reverse
genetics, we rationally designed a novel RSV LAV OE4 that
incorporated line 19F into the genotype RSV-A2-dNS1-dNS2-
DSH-dGm-GSnull-line19F. In addition to being thermally and
genetically stable, OE4 was also highly immunogenic and
efficacious despite significant attenuation in vitro and in vivo.
These data demonstrate that we fundamentally altered RSV
immunogenicity and generated a promising LAV candidate that
merits further investigation.
Methods
Cells and animals. HEp-2 (ATCC CCL-23) and Vero (ATCC CCL-81) were
cultured in minimal essential medium (MEM) containing 10% fetal bovine
serum (FBS) and 1 mgml 1 penicillin, streptomycin and amphotericin B (PSA)8.
BSR-T7/5 (a gift from Ursula Buchholz, National Institutes of Health,
Bethesda, MD) were cultured in Glasgow’s minimal essential medium (GMEM)
containing 10% FBS and 1 mgml 1 PSA supplemented with 1mgml 1
Geneticin with every other passage8. BEAS-2B cells (ATCC CRL-9609) were
cultured in RMPI containing 10% FBA and 1 mgml 1 PSA44. The cell lines were
not authenticated, and they were negative for mycoplasma using the LookOut
Mycoplasma detection kit (Sigma). Normal human bronchial epithelial (NHBE)
cells were purchased from Lonza and differentiated 4–6 weeks at air–liquid
interface (ALI) as described8. Prior to infection, NHBE-ALI cultures exhibited
trans-epithelial resistance. Human airway epithelial (HAE) cells from airway
specimens of patients without defined lung disease were isolated by the University
of North Carolina (UNC) Marsico Lung Institute Tissue Culture Core45. Patients
provided informed consent under UNC at Chapel Hill Institutional Review
Board-approved protocols from the National Disease Research Interchange
(NDRI, Philadelphia, PA). Primary cells were cultured initially in a cell culture-
treated flask before being seeded at a density of 3 105 cells per Transwell disk.
Similar to NHBE cells, HAE cells were cultured at ALI for 4–6 weeks forming
differentiated polarized cultures45.
Six- to eight-week-old female BALB/c mice (The Jackson Laboratory or Charles
River) were maintained under pathogen-free conditions until the time of use. The
Emory University Institutional Animal Care and Use Committee (IACUC)
approved the mouse studies. Male and female Sigmodon hispidus cotton rats were
bred and housed in the vivarium in Baylor College of Medicine. These cotton rats
were B75 to 150 g of body weight at the start of the experiments, and all
experimental protocols were approved by the Baylor College of Medicine’s IACUC.
Inbred Sigmodon hispidus cotton rats at Sigmovir Biosystems, Inc. (Rockville, MD)
were utilized in a challenge study approved by the Sigmovir IACUC. All mouse and
cotton rat experiments were conducted in accordance with the Guide for Care and
Use of Laboratory Animals of the National Institutes of Health, as well as local,
state and federal laws. Mice and cotton rats were randomly assigned to groups
based on sequential selection from an inventory, and investigators were not blinded
to outcome assessment.
Assembly and rescue of recombinant RSV viruses. The following recombinant
viruses were previously described: A2, A2-line19F, A2-line19F(M79I),
A2-line19F(R191K), A2-line19F(K357T), A2-line19F(Y371N), A2-line19F(I557V),
A2-line19F(K357T/Y371N) and A2-mKate2-2-20F/G20,41,46. The bacterial artificial
chromosome (BAC) construct for OE4 was generated through modification of the
published BAC containing A2-mKate2-line19F(I557V)41. The gene for monomeric
Katushka 2 (mKate2, K), a far-red fluorescent reporter, is in the first gene position
of the RSV antigenomic cDNA. Inclusion of mKate2 in this position did not
attenuate RSV in vitro or in mice41. Deletion of SH (DSH) was performed by
recombination-mediated mutagenesis (recombineering)41. The following
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oligonucleotides (Integrated DNA Technologies/IDT) were used to PCR-amplify
the galK cassette such that the amplicon termini are homologous to the target site
to replace SH with galK: dSH50f (50-AGATCTAGTACTCAAATAAGTTAATAA
AAAATATACACATGGACGTCCATCCTGTTGACAATTAATCATCGGCA-30),
where the underlined portions represent the 50 nt immediately upstream of the SH
gene start in the BAC, and dSH50r (50-GTCTTAGCGGTGCGTTGGTCCTTGTT
TTTGGACATGTTTGCATTTGCCCCTCAGCACTGTCCTGCTCCTT-30), where
the underlined portion represents the complement of 50 nt beginning with the
G gene start in the BAC. The non-underlined portions of the primers are specific to
the galK cassette, as described41. Recombination in E coli resulted in replacing SH,
from the beginning of the gene start to the end of the SH-G intergenic region, with
the galK cassette. The following complementary oligonucleotides were annealed
and used for removing the galK cassette in the second step of recombineering:
dSH100f (50-AGATCTAGTACTCAAATAAGTTAATAAAAAATATACA
CATGGACGTCCATGGGGCAAATGCAAACATGTCCAAAAACAAGGAC-
CAACGCACCGCTAAGAC-30) and dSH100r (50-GTCTTAGCGGTGCGTTGG
TCCTTGTTTTTGGACATGTTTGCATTTGCCCCATGGACGTCCATGTGTA-
TATTTTTTATTAACTTATTTGAGTACTAGATCT-30). Precise deletion of
SH was confirmed by sequencing, yielding A2-K-DSH-line19F(I557V) BAC.
The human codon-deoptimized NS1 (Supplementary Fig. 5) and NS2
(Supplementary Fig. 6) coding regions were digested from the BAC used
for recovery of A2-dNSh previously described and ligated into the A2-K-DSH-
line19F(I557V) BAC yielding an A2-K-dNSh-DSH-line19F(I557V)8. This
construct was used for recovery of OE4þwild-type A2 G (termed OE4þwtG).
Codon deoptimization of G was performed through substitution in silico of all
codons least frequently used based on human codon usage bias into the RSV G
sequence of A2. A point mutation (M48I) was introduced to ablate the secreted
form of G (Supplementary Fig. 7). The coding region of codon-deoptimized G (dG)
was synthesized by GenScript and cloned by restriction digestion and ligation into
the A2-K-dNSh-DSH-line19F(I557V) BAC yielding A2-K-dNSh-DSH-dG-
line19F(I557V) yielding the recovery BAC for OE4. The rescue of DB1 was
previously described9. DB1–357/371 was generated through introduction of the
line 19F residues K357 and Y371 into the DB1 coding sequence. The BAC for
rescue of A2-del-M2-2 was generated by recombineering. We deleted 234 nt
(from the seventh codon to the stop codon) of M2-2, as had been done previously
for RSV DM2-2 (ref. 47). The following oligonucleotides were used to PRC-amplify
the galK cassette for the first step of recombineering, delM2-1-f (50-TTAGTGA
TACAAATGACCATGCCAAAAATAATGATACTACCTGACAAATACCTGTT-
GACAATTAATCATCGGCA-30) and delM2-2-r (50-ATTGTTTGAATTA
ATAATGTAACGATGTGGTGAGTGTTAGAATTGAGTGTTCAGCACTGTC
CTGCTCCTT-30). The following complementary oligonucleotides were annealed
and used for the second recombineering step, M22_100f (50-TTAGTGATACAAA
TGACCATGCCAAAAATAATGATACTACCTGACAAATAACACTCAATTC-
TAACACTCACCACATCGTTACATTATTAATTCAAACAAT-30), and
M22_100r (50-ATTGTTTGAATTAATAATGTAACGATGTGGTGAGTGT
TAGAATTGAGTGTTATTTGTCAGGTAGTATCATTATTTTTGGCATGGT-
CATTTGTATCACTAA-30). Precise deletion of the targeted 234 nt was confirmed
by sequencing. A version of OE4 without the mKate2 gene was also generated from
pSynkRSV-dNS1-dNS2-DSH-line19F by excising the coding region containing
the mKate2 gene with KpnI and AvrII. The resultant fragment containing mKate2
flanked by identical BlpI sites was then excised using BlpI, and the flanking
fragments were ligated to generate pSynkRSV-dNS1-dNS2-DSH-line19F
without mKate2. Recombinant viruses described in this paragraph were rescued in
BSR-T7/5 cells41, and virus stocks were propagated in Vero cells.
The panel of RSV strains used for quantification of RSV nAb titres in cotton
rat anti-sera were generated by first having cDNAs of F and G genes of the
following A and B strains synthesized (GeneArt, Invitrogen): RSVA/1998/12-21
(JX069802), Riyadh A/91/2009 (JF714706/JF714710); and RSV B strains NH1276
(JQ680988/JQ736678), 9320 (AY353550), and TX11-56 (JQ680989JQ736679). The
G and F gene segments were cloned into the A2-K BAC by restriction digestion
and ligation, and the reporter viruses were recovered by transfection into BSR-T7/5
cells, followed by propagation of stocks in HEp-2 cells as was previously described9.
RSV thermal stability. Virus aliquots were thawed at room temperature, pooled
in 15ml conical tubes, and mixed 1:1 with serum-free MEM before vortexing for
30 s. After vortexing, 1.5ml of each virus suspension was transferred to replicate
tubes to be incubated at either 4 or 37 C in water baths. At designated time points,
the tubes containing virus suspensions were removed, vortexed for 30 s each, and
300ml was transferred to tubes then frozen in liquid nitrogen and stored at
 80 C. Quantification of titre was either determined by counting fluorescent
focus units (FFU), if the virus was mKate2-expressing, or by plaque assay. For
quantification by FFU titre, after all time points had been collected, samples were
thawed on ice, vortexed 30 s, and serially diluted by 10-fold reductions in
serum-free MEM in a 96 well plate. Once serially diluted, 50 ml of each dilution in
triplicate was transferred to a 96-well plate containing confluent Vero cells. The
virus was spinoculated onto the cells at 2,900g for 30min at 4 C before being
overlaid with a 0.75% methylcellulose suspension in complete MEM. The plates
were incubated at 37 C for 2 days before FFU were counted. The methods for
plaque assay have been previously described20. Plates of Vero cells infected for
immunoplaque assay were incubated at 37 C for 6 days prior to processing.
Pre-F antigen ELISAs. Virus aliquots were thawed and diluted in MEM to yield
high-titre stock suspensions. Then 100 ml of each virus stock suspension was added
in triplicate to wells in a 96-well Costar Assay Plate, High Binding (Corning).
The plates were covered and incubated at room temperature overnight. The next
day, the virus suspension was dumped from the plate, and the plate was washed
once with 150 ml per well of PBS-Tween (PBST, 0.05% Tween20 in PBS) followed
by addition of 150 ml of 5% BSA (in PBS) per well for blocking. The plate was
incubated at room temperature for 2 h. Pre-F-specific mAb MPE8 (ref. 19) was
generated in HEK293-X2FreeStyle cells (U-Protein Express, BV) using human
codon-optimized VH and VL sequences. Motavizumab mAb which binds pre-F and
post-F was kindly provided by Nancy Ulbrandt (MedImmune/AZ). MPE8 and
motavizumab antibodies were prepared by diluting the antibodies to 1 mgml 1 in
PBS before further dilution of 1:10,000 to 1:320,000 by serial dilutions in 1% BSA.
Following blocking, the plate was washed once again with 150 ml per well of PBST
before 100ml of the serially diluted primary antibodies were applied to the wells.
The plate was incubated for 2 h at room temperature before being dumped and
washed three times with 150 ml per well of PBST. After washing, 100 ml of a
1:10,000 dilution of anti-human-HRP antibody in 1% BSA was applied and the
plate incubated for 1 h at room temperature. Then the plate was dumped and
washed three times with 150 ml of PBST before 100 ml of a pre-mixed reactive
substrate reagent mixture (R&D Systems) was applied to catalyse a colorimetric
reaction. The plate was covered and incubated forB10min before the reaction was
quenched by the addition of 100 ml of 0.2N sulfuric acid. The plate was read at
450 nm on an ELISA plate reader. Background absorbance levels were subtracted
from the test sample absorbance readings and plotted to a curve. The ratio of the
area under the curve for MPE8 (pre-F) to the area under the curve for
motavizumab (pre-F and post-F, total F) was calculated to determine pre-F level
normalized to total F. The identical ELISA procedure was replicated using D25
instead of MPE8 as an additional measure of pre-F antigen levels.
To determine the stability of pre-F in OE4 compared with A2 at 4 C over time,
we incubated vials of virus for 0, 3 or 7 days and similarly applied 100 ml of each
virus stock suspension in triplicate to wells in a 96-well Costar plate. We incubated
the plates at 4 C overnight, such that the final time points at time of measurement
were 1, 4 and 8 days, respectively. We then performed ELISAs using MPE8 and
motavizumab as above, but kept the plates and substrates at 4 C or on ice for the
remainder of the experiment.
Western blotting. Western blots were performed on infected Vero cell lysates
harvested in RIPA buffer as described8 using polyclonal rabbit antisera specific
to NS1 (1:5,000) and NS2 (1:400; gifts from Michael Teng, USF Health), D14
(1:5,000; anti-RSV N; gift from Edward Walsh, University of Rochester), 131-2G
(1:2,000; anti-RSV G, MAB858-2-5; Millipore), motavizumab (1:5,000; anti-F; gift
from Nancy Ulbrant) or GAPDH (1:5,000), followed by peroxidase-conjugated
anti-rabbit, anti-mouse or anti-human secondary antibodies (1:10,000; Jackson
ImmunoResearch) (Fig. 3 and Supplementary Fig. 8). Densitometry analyses were
performed using Image Lab software (Bio-Rad).
Viral replication in immortalized and primary cell cultures. The media from
70% confluent Vero or BEAS-2B cells in six-well plates was aspirated, and 0.5ml of
virus at a multiplicity of infection (MOI) of 0.01 was added to replicate wells for
each of the time points to be acquired for each virus strain. The plates were rocked
at room temperature for 1 h. Following infection, the virus was carefully aspirated
and the monolayers washed twice with 1ml of PBS before 2ml of pre-warmed
complete E-MEM (Vero) or RPMI (BEAS-2B) was added. The plates were incu-
bated at 37 C and 5% CO2 for the duration of the time courses. Time points were
acquired at 1, 12, 24, 36, 48, 72 and 96 h post infection. At each time point, the
monolayers were scrapped into the supernatant, vortexed briefly and flash frozen in
liquid nitrogen before storage at  80 C. NHBE cells from two donors were
differentiated at ALI and the monolayers washed with PBS before being infected
apically with 100 ml of virus at an MOI of 2.6. The virus was left to incubate for 2 h
at 37 C before removal and three subsequent washes with PBS. At designated time
points, 150ml of differentiated medium without inducer was incubated on the
apical surface for 10min at 37 C before harvesting and transfer into micro-
centrifuge tubes. The process was repeated to yield a total of 300 ml of pooled apical
wash, which was frozen in liquid nitrogen and stored at  80 C for later titration.
Similar to the NHBE infection, HAE cells from two donors were differentiated at
ALI, the apical surface washed with PBS, and infected with an initial MOI of 6.7.
Following 2 h incubation at 37 C, the virus inoculum was aspirated, the apical
layer washed three times with PBS and the culture incubated at 37 C. For each
designated time point, the apical layers were washed with 425 ml of media for
30min at 37 C and the supernatant stored at  80 C. FFU titration was per-
formed for all analyses as described above on either HEp-2 or Vero cells.
Attenuation and efficacy in mice. For determination of viral load, 7-week-old
female BALB/c mice (Charles River) were infected i.n. under sedation with 100 ml
of virus in serum-free MEM. On days 2, 4, 6 and 8, the mice were euthanized and
the left lung harvested and homogenized for viral FFU titre assay. Titres below the
limit of detection were assigned a value equal to half of the limit of detection. To
assess the genetic stability of OE4 NS1, NS2, F and G genes in vivo, we also used the
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13916 ARTICLE
NATURE COMMUNICATIONS | 7:13916 | DOI: 10.1038/ncomms13916 | www.nature.com/naturecommunications 9
lung homogenate from day 6 post infection to sequence the genes of interest after
passage in mice. We first isolated viral RNA directly
from lung homogenate using Nucleospin RNA purification kit (Macherey-Nagel)
and performed reverse transcription using SuperScript III reverse transcriptase
(Thermo-Fisher). We then amplified regions of interest using PfuTurbo DNA
polymerase (Agilent) and obtained sequences via GenHunter Corp.
For determination of serum nAb titres and challenge studies, 7-week-old female
BALB/c mice (Jackson) were infected i.n. with 100ml of virus in serum-free MEM.
On days 35, 70 and 100, the mice were sedated and serum samples obtained via
submandibular vein bleeding. Sera were stored at  80 C until quantification
by a FFU microneutralization assay8. Neutralization titres were determined by
co-incubating heat-inactivated (56 C, 30min) sera, which had been two-fold
serially diluted with 50–100 FFU of virus for 1 h at 37 C. The serum-virus
mixtures were then spinoculated onto HEp-2 monolayers in 96-well plates at
2,900g for 30min at 4 C before being overlaid with 0.75% methylcellulose in
complete MEM. FFU per well were counted 2 days later, and EC50 titres were
determined by nonlinear regression analysis (GraphPad Prism). To challenge the
mice after vaccination, the mice were sedated on day 102 post inoculation and
infected i.n. with 105 PFU A2-line19F. After 4 days, the viral load was determined
on the left lung by plaque assay on HEp-2 cells.
Histopathology in mice. Female 8-week-old BALB/c mice (Jackson) were sedated
and infected intranasally with either mock solution or 105 FFU of A2, A2-line19F,
OE4 or A2-del-M2-2. After 8 days, the lungs were harvested, fixed, sectioned and
stained with Periodic acid-Schiff (PAS). Morphometric quantification of airway
PAS positivity was performed on digitized slides using a Mirax digital pathology
system (Zeiss) and Histoquant software as previously described20. All airways in
the sections were analysed.
Attenuation and efficacy in cotton rats. For determination of viral load in naive
animals, 8- to 10-week-old male and female cotton rats were sedated and inocu-
lated i.n. with 105 FFU of virus in 100 ml in serum-free MEM at Baylor College of
Medicine. On day 4 post infection, the cotton rats were killed. For acquisition of
lung lavage washes, the left lobe of the lung was excised and transpleurally lavaged
with 3ml of Iscove’s media with 15% glycerin mixed
with 2% FBS-MEM (1:1). For acquisition of nasal wash, the jaws were first
disarticulated and the head was removed. A solution of 1ml of Iscove’s media with
15% glycerin mixed with 2% FBS-MEM (1:1) was washed through each nare for a
total of 2ml of volume. Titration was performed by plaque assay on HEp-2 cell
monolayers. For determination of nAb titres, 8- to 10-week-old male and female
cotton rats at Baylor College of Medicine were sedated and inoculated i.n. with
105 FFU of virus in 100 ml of serum-free MEM. On day 42, serum was obtained
via the orbital plexus of the cotton rats and stored at  80 C until analysed as
described above. To assess efficacy, cotton rats were challenged on day 42 post
infection (following i.n. vaccination with 3 105 FFU) with 1 106 FFU i.n. of
RSV strain A2-line19F at Sigmovir Biosystems Inc. On day 4 post challenge, the
nasal turbinates were homogenized in 3ml of HBSS supplemented with 10% SPG,
and the left lung was homogenized in 3ml of HBSS supplemented with 10% SPG.
The nasal and lung tissue titres were determined by plaque assay as described
above.
Enhanced disease study in cotton rats. Groups of five 6- to 8-week-old
female cotton rats were vaccinated intranasally with either 105 FFU of OE4, MEM
(mock treatment), or intramuscularly with FI-RSV (lot 100; 1:125) at Sigmovir, Inc.
On day 21, FI-RSV-vaccinated rats were boosted with a second identical
vaccination. On day 42, all cotton rats were challenged intranasally with
1.35 105 PFU of A2-line19F. On day 48 (day 6 post challenge), the cotton rats
were killed and the lungs excised, perfused with 10% formalin and sections of
paraffin-embedded inflated lungs were stained with hematoxylin-eosin (H&E). The
slides were scored by a pathologist blinded to the groups on a scale of 0 to 4 based
on increasing severity of peribronchial mononuclear inflammatory cell infiltration,
perivascular mononuclear inflammatory cell infiltration, interstitial pneumonitis
and alveolitis.
Cryo-ET. BEAS-2B cells were seeded on gold R2/1 Quantifoil TEM grids in
MatTek dishes and were infected when subconfluent (30–40%) at an MOI of
10 using A2 and OE4 strains. Twenty-four hours post infection, infected cells on
gold Quantifoil TEM grids were plunge frozen using a Gatan CryoPlunge 3
apparatus (Gatan, Inc., Pleasanton, CA). For the A2 strain that was heat-treated,
BEAS-2B cells were seeded on gold R2/1 Quantifoil TEM grids in MatTek dishes
and were infected when subconfluent (30–40%) at an MOI of 10 with the A2 strain.
Twenty-four hours post infection, the MatTek dishes containing TEM grids were
incubated for 30min at 55 C (ref. 23). Immediately after heat treatment,
infected cells on gold Quantifoil TEM grids were plunge frozen using a CryoPlunge
3 apparatus. In all instances, 4 ml of BSA-conjugated 10 nm gold nanoparticles was
applied onto the TEM grid prior to cryoplunging. Cryogrids were stored in
liquid nitrogen prior to imaging with a JEOL JEM-2200FS TEM at 200 kV
(JEOL Ltd., Japan), which is equipped with a field emission gun, an
in-column Omega energy filter with a slit width of 20 eV. Tilt series were recorded
semi-automatically using the SerialEM package from  65 to 65 at 2 increment
step,  6 mm defocus, with a total dose of B120 e Å 2 (refs 17,38,48,49).
Images were recorded on a Direct Electron DE-20 camera (Direct Electron, LP,
San Diego, CA) at 12 frames per second at a nominal magnification of 10,000
resulting in a pixel size of 0.614 nm.
Tilt series frames were motion corrected prior to tomographic reconstruction
using python scripts provided by the manufacturer (Direct Electron, LP). Motion
corrected frames were used for tomographic reconstruction in the IMOD software
package using the weighted back-projection algorithm, and the 10 nm gold
nanoparticles were used as fiducials to align frames at the different tilt angles50.
Reconstructed three-dimensional volumes (unbinned and binned by a factor of 2)
were also CTF-corrected by inversing the phase and de-noised by nonlinear
anisotropic diffusion.
Subvolume averaging and model fitting. Subvolumes of RSV glycoproteins were
manually selected (3,827, 2,567 and 1,313 subvolumes for A2, OE4 and
A2-heat, respectively) from tomograms binned by a factor of 2, using EMAN2
e2spt_boxer.py script51. Initially, two-fold binned data were used in the subvolume
averaging process. Alignments and averaging were performed in PEET 1.11.0
Alpha version, and each subvolume was normalized (‘flgNormalize¼ 1’) prior to
alignment and averaging52. Initial orientations of the subvolumes were determined
using SpikeInit. Particles were considered duplicates if the centre-to-centre distance
was o60Å for A2 and OE4 and 40Å for A2-heat samples; only the ones with the
highest cross-correlation coefficient values were kept. The initial reference was a
previously published post-fusion F glycoprotein (EMDB-2393) low-pass filtered to
60Å. A soft-edged cylinder mask was applied during alignment to eliminate
contributions from the neighbouring particles. Using the two-fold binned data, six
iterations were run with missing wedge compensation (eight weight groups) and
the resulting averages indicated three-fold symmetry, consistent with the crystal
structures. Thus, we imposed C3 symmetry by creating a three-fold symmetric data
set: the first set are the aligned particles, the second and third sets have all the same
tilt angles and positions as the first set, but with either 120 or 240 of twist
rotation along the y axis applied using modifyMotiveList in PEET. The initial
subvolume averages were used as references for refinements with C3 symmetry
imposed, and three more iterative refinements were run with smaller transitional
and angular search ranges and increasing high-frequency cutoff values. The
respective translation information from the two-fold binned data were scaled by a
factor of two to match the unbinned tomograms, and were used as input
MotiveList for three more iterative refinements on the unbinned data. The final
subvolume averages (final pixel size of 6.14Å, unbinned) with C3 symmetry were
reconstructed from 2,268, 1,687 and 823 subvolumes, for A2, OE4 and A2-heat,
respectively. The final density maps of F were low-pass filtered to FSC¼ 0.143
cutoff calculated in PEET, and masked using a soft edged cylinder generated using
SPIDER53. The atomic crystal structures of pre-fusion and post-fusion F
glycoprotein (PDB IDs 4JHW and 3RRT, respectively) were manually fitted into
the final electron density maps using Chimera54.
Immuno-TEM. BEAS-2B cells were seeded on Alcar disks in 24-well plates and
were infected when subconfluent (50–70%) at an MOI of 10 using A2 and OE4
strains. Twenty-four hours post infection, anti-pre-F (MPE8)19, anti-post-F
(131-2A)33,55, anti-F (motavizumab, gift from Nancy Ulbrant) and anti-G (131-2G,
MAB858-2-5; Millipore), primary antibodies were added to RPMI-1640 medium at
a final concentration of 5 mgml 1. After primary antibody incubation for 1.5 h at
37 C, cells were washed four times with RPMI-1640 medium, and then incubated
for 1.5 h at 37 C with goat anti-human (used for MPE8 and motavizumab) or goat
anti-mouse (used for 131-2A and 131-2G) secondary antibody conjugated to 6 nm
gold particles in RPMI-1640 medium at a final concentration of 10–20 mgml 1.
Following additional medium washes, cells were fixed in 2.5% glutaraldehyde at
4 C overnight. The next day, fixed cells on Aclar disks were washed with 0.1M
phosphate butter (pH 7.4) followed by pre-fixation with 1% OsO4 in 0.1M
phosphate buffer for 1 h. The cells were then washed with deionized water before
dehydration at 5min intervals in graded concentrations of ethanol (25, 50, 75, 95
and 100%). The cells were then treated with a 1:1 resin mixture of 100% ethanol
and Eponate 12 for 1 h, followed by polymerization with 100% Eponate 12 resin
overnight in the oven. Ultrathin sections were cut between 60 and 80 nm in
thickness, and then stained using 5% uranyl acetate and 2% lead citrate. Sections
were imaged as montages using SerialEM software on a JEOL JEM-1400 TEM
(JEOL Ltd., Japan) equipped with a Gatan US1000 2 k 2 k CCD camera (Gatan)
at  8,000 nominal magnification17,18,56.
Montages were assembled using sloppyblend.com script, and further
measurements and quantification were done using the blended maps. The six
groups of data (70 montages, 1,515 viral particles) were randomly blinded
among groups prior to quantification. Total membrane length of a viral particle
was measured using imodinfo command by placing open model points along the
viral membrane, where distinct membrane morphology is present. The 6 nm
immunogold particles on both sides of viral particle membranes were counted
separately. Gold particle intensity per particle was calculated using total gold
particles on the viral membrane divided by total viral membrane length
(gold particles per mm of membrane length). Representative images for the
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immuno-TEM were selected based on the average gold particle intensities along the
membrane.
Statistical analyses. All statistical analyses were computationally performed
using GraphPad Prism. The number of replicates and type of statistical analysis
performed are described for all experiments in the figure legends. No statistical
methods were used in predetermining sample sizes.
Data availability. All relevant data are available from the authors upon request.
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